Avila Therapeutics to Present at the 2011American Society of Hematology Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that two poster presentations on AVL-292, a highly selective Bruton’s tyrosine kinase (Btk) inhibitor being evaluated for the treatment of several hematologic cancers, will be presented at the 2011 American Society of Hematology (ASH) Annual meeting taking place on December 10-13, 2011 in San Diego, CA.